SAN DIEGO, April 24, 2017 /PRNewswire/ -- Denovo Biopharma
LLC, today announced that it has obtained an exclusive license to
liafensine (DB104), a serotonin-norepinephrine-dopamine reuptake
inhibitor (SNDRI), a late-stage CNS drug, from Albany Molecular
Research, Inc. (NASDAQ: AMRI). The agreement between Denovo
Biopharma and AMRI concludes AMRI's divesture of all its legacy
intellectual property assets. Under the terms of the
definitive agreement, Denovo Biopharma gains an exclusive license
to all rights to develop, manufacture and commercialize liafensine
globally. Liafensine represents the third late stage product in
Denovo Biopharma's pipeline.
Liafensine was taken through significant preclinical research,
early development and subsequently multiple phase 2 clinical
studies in treatment-resistant depression were conducted.
Liafensine was well tolerated, with no evidence of dose-dependent
discontinuations due to adverse events, however, the program was
not continued beyond phase 2 studies.
"We appreciate the extensive efforts in the development of
liafensine to date. We will apply our biomarker platform to analyze
prior clinical data and identify genomic biomarkers that correlate
with patients' responsiveness to treatment. This will help to
establish a biomarker-drive clinical study into which the
appropriate patient subsets will be enrolled. We are very excited
to have the opportunity to develop a biomarker driven treatment for
people with depression," said Wen
Luo, PhD., Denovo Biopharma's CEO.
"Liafensine (DB104) is our third late-stage asset, and we can
now build on the success of DB102 (enzastaurin) where we have
identified biomarkers and are initiating a phase 3 clinical study
later this year. We will continue to seek additional late stage
product opportunities which could benefit from Denovo's unique
biomarker platform," said Robert
Little, Denovo Biopharma's CBO.
About Denovo Biopharma LLC
Denovo Biopharma is a biopharmaceutical company providing novel
biomarker approaches to personalized drug development, including
re-evaluating medicines that have failed in general patient
populations. The company offers the first platform and algorithm
for de novo genomic biomarker discovery using archived
clinical samples. By identifying biomarkers correlated with
patients' responses to drug candidates retrospectively, Denovo
Biopharma enables the design and execution of follow-on clinical
trials in targeted patient populations while optimizing efficacy,
safety and tolerability. For additional information please visit
www.denovobiopharma.com.
Contact:
Robert Little,
Chief Business Officer
Denovo Biopharma LLC
(858) 876-4012
rlittle@denovobiopharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/denovo-biopharma-obtains-exclusive-license-to-liafensine-from-amri-300443950.html
SOURCE Denovo Biopharma, LLC